Staidson (Beijing) BioPharmaceuticals (SHE:300204) released the preliminary results for clinical trials for a drug that will treat patients with acute respiratory distress syndrome or ARDS, according to a Shenzhen bourse filing on Wednesday.

The Phase Ib/II clinical trials, which evaluates the safety and efficiency of the STSA-1002 injection, found that the drug showed mortality reductions of 33% and 85% for the low-dose and high-dose groups, respectively. The drug also showed clinical improvement rates of more than 70% for both groups.

The clinical trials received approval from the Chinese drug administration in March, the biopharmaceutical company said.

Staidson Bio's shares surged 20% in recent trade.